Genelux Corporation (GNLX)

NASDAQ: GNLX · IEX Real-Time Price · USD
8.46
+0.36 (4.38%)
Feb 27, 2024, 11:39 AM EST - Market open
4.38%
Market Cap 178.21M
Revenue (ttm) 238,000
Net Income (ttm) -25.03M
Shares Out 26.72M
EPS (ttm) -1.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 57,840
Open 8.16
Previous Close 8.10
Day's Range 7.67 - 8.51
52-Week Range 6.40 - 40.98
Beta n/a
Analysts Strong Buy
Price Target 32.50 (+284.16%)
Earnings Date Mar 12, 2024

About GNLX

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement wi... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 26, 2023
Employees 22
Stock Exchange NASDAQ
Ticker Symbol GNLX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for GNLX stock is "Strong Buy." The 12-month stock price forecast is $32.5, which is an increase of 284.16% from the latest price.

Price Target
$32.5
(284.16% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance and...

3 months ago - GlobeNewsWire

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

- Expanded executive team as Lourie Zak appointed Chief Financial Officer -  - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalents - ...

3 months ago - GlobeNewsWire

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the Company'...

5 months ago - GlobeNewsWire

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairma...

6 months ago - GlobeNewsWire

Genelux Corporation Announces New Chief Financial Officer

WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the company ...

6 months ago - GlobeNewsWire

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

- Inclusion into the broad-market Russell 3000® Index and small-cap Russell 2000® Index - - Publication of VIRO-15 Phase 2 data in JAMA Oncology - - $51 Million raised after closing of two private pla...

7 months ago - GlobeNewsWire

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

WESTLAKE VILLAGE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and ...

7 months ago - GlobeNewsWire

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as well as...

7 months ago - GlobeNewsWire

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

WESTLAKE VILLAGE, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication in Frontiers in Immunolog...

8 months ago - GlobeNewsWire

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

- V2ACT Therapeutics™, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. - V2ACT Immunotherapy is a proprietary immuno-oncology modality composed of Olvi-Vec (oncolytic vira...

8 months ago - GlobeNewsWire

Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad-market...

8 months ago - GlobeNewsWire

Genelux Corporation Announces $18 Million Private Placement

WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares of...

9 months ago - GlobeNewsWire

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology

WESTLAKE VILLAGE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication of positive topline result...

9 months ago - GlobeNewsWire

Genelux Corporation Announces $33 Million Private Placement

WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of...

10 months ago - GlobeNewsWire

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on developing a pi...

1 year ago - GlobeNewsWire

Genelux IPO prices at bottom of range

Genelux Corp. priced its initial public offering at $6 a share, the low end of its $6 to $7 a share range, for its stock market debut Thursday on the Nasdaq under the symbol GNLX. With 2.5 million sha...

1 year ago - Market Watch

Genelux Corporation Announces Pricing of Initial Public Offering

WESTLAKE VILLAGE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux” or “the Company”), a clinical-stage immunotherapy company focused on developing a pipeline of next-generation...

1 year ago - GlobeNewsWire

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

Genelux Corp. GNLX, has set terms for its initial public offering, in which the California-based biotechnology company focused on treating difficult-to-treat tumors could be valued at up to $164.99 mi...

1 year ago - Market Watch